AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 115 filers reported holding AKERO THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $9,857,283 | +6.2% | 194,885 | -2.0% | 0.00% | 0.0% |
Q2 2023 | $9,282,859 | +4.8% | 198,819 | -14.1% | 0.00% | 0.0% |
Q1 2023 | $8,854,167 | -20.2% | 231,421 | +14.3% | 0.00% | 0.0% |
Q4 2022 | $11,090,917 | +363.3% | 202,389 | +187.8% | 0.00% | – |
Q3 2022 | $2,394,000 | +559.5% | 70,320 | +82.8% | 0.00% | – |
Q2 2022 | $363,000 | -58.9% | 38,478 | -38.2% | 0.00% | – |
Q1 2022 | $883,000 | +4.9% | 62,241 | +56.4% | 0.00% | – |
Q4 2021 | $842,000 | -30.3% | 39,789 | -26.4% | 0.00% | – |
Q3 2021 | $1,208,000 | +456.7% | 54,049 | +517.7% | 0.00% | – |
Q2 2021 | $217,000 | -29.5% | 8,750 | -17.7% | 0.00% | – |
Q1 2021 | $308,000 | +58.8% | 10,638 | +41.2% | 0.00% | – |
Q4 2020 | $194,000 | -80.4% | 7,532 | -76.6% | 0.00% | – |
Q3 2020 | $991,000 | +348.4% | 32,196 | +262.8% | 0.00% | – |
Q2 2020 | $221,000 | +281.0% | 8,875 | +222.8% | 0.00% | – |
Q1 2020 | $58,000 | -56.1% | 2,749 | -53.9% | 0.00% | – |
Q4 2019 | $132,000 | +187.0% | 5,958 | +203.8% | 0.00% | – |
Q3 2019 | $46,000 | – | 1,961 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ATP Life Science Ventures, L.P. | 5,830,203 | $179,512,000 | 24.20% |
venBio Partners LLC | 2,444,311 | $75,260,000 | 11.44% |
Versant Venture Management, LLC | 777,727 | $23,946,000 | 4.38% |
Redmile Group, LLC | 2,336,357 | $71,936,000 | 1.32% |
Vivo Capital, LLC | 571,833 | $17,607,000 | 1.02% |
Cormorant Asset Management, LP | 859,550 | $26,466,000 | 1.02% |
Boxer Capital, LLC | 831,495 | $25,602,000 | 0.88% |
Integral Health Asset Management, LLC | 85,000 | $2,617,000 | 0.80% |
EAM Global Investors LLC | 49,718 | $1,531,000 | 0.56% |
Crawford Lake Capital Management, LLC | 43,826 | $1,349,000 | 0.56% |